126 related articles for article (PubMed ID: 32653455)
41. Socioeconomic differences in patient survival are increasing for acute myeloid leukemia and multiple myeloma in sweden.
Kristinsson SY; Derolf AR; Edgren G; Dickman PW; Björkholm M
J Clin Oncol; 2009 Apr; 27(12):2073-80. PubMed ID: 19289627
[TBL] [Abstract][Full Text] [Related]
42. Prognostic Value of Baseline
Moon SH; Choi WH; Yoo IR; Lee SJ; Paeng JC; Jeong SY; Lee SW; Kim K; Choi JY
Korean J Radiol; 2018; 19(3):481-488. PubMed ID: 29713226
[TBL] [Abstract][Full Text] [Related]
43. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
44. Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma.
Cejalvo MJ; Bustamante G; González E; Vázquez-Álvarez J; García R; Ramírez-Payer Á; Pérez-Persona E; Abella E; Garzón S; García A; Jarque I; González MS; Sampol A; Motlló C; Martí JM; Alcalá M; Duro R; González Y; Sastre JL; Sarrà J; Lostaunau G; López R; de la Rubia J
Ann Hematol; 2021 Jul; 100(7):1769-1778. PubMed ID: 33885924
[TBL] [Abstract][Full Text] [Related]
45. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
[TBL] [Abstract][Full Text] [Related]
46. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects.
Sergentanis TN; Kastritis E; Terpos E; Dimopoulos MA; Psaltopoulou T
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):335-40. PubMed ID: 27101987
[TBL] [Abstract][Full Text] [Related]
47. The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.
Bila J; Jelicic J; Dencic Fekete M; Trajkovic G; Sretenovic A; Perunicic Jovanovic M; Antic D; Mihaljevic B
Oncol Res Treat; 2017; 40(10):616-620. PubMed ID: 28950269
[TBL] [Abstract][Full Text] [Related]
48. Socioeconomic status and breast cancer survival in Pakistani women.
Aziz Z; Sana S; Akram M; Saeed A
J Pak Med Assoc; 2004 Sep; 54(9):448-53. PubMed ID: 15518365
[TBL] [Abstract][Full Text] [Related]
49. Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma.
Tandon N; Sidana S; Rajkumar SV; Gertz MA; Buadi FK; Lacy MQ; Kapoor P; Gonsalves WI; Dispenzieri A; Kourelis TV; Warsame R; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Hwa YL; Kyle RA; Leung N; Go RS; Lust JA; Russell SJ; Kumar SK
Blood Adv; 2019 Mar; 3(5):744-750. PubMed ID: 30824418
[TBL] [Abstract][Full Text] [Related]
50. Education level as a predictor of survival in patients with multiple myeloma.
Xu L; Wang X; Pan X; Wang X; Wang Q; Wu B; Cai J; Zhao Y; Chen L; Li W; Li J
BMC Cancer; 2020 Aug; 20(1):737. PubMed ID: 32770980
[TBL] [Abstract][Full Text] [Related]
51. The independent association of mean platelet volume with overall survival in multiple myeloma.
Zhuang Q; Xiang L; Xu H; Fang F; Xing C; Liang B; Yu K; Feng J
Oncotarget; 2016 Sep; 7(38):62640-62646. PubMed ID: 27566590
[TBL] [Abstract][Full Text] [Related]
52. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.
Gopalakrishnan S; D'Souza A; Scott E; Fraser R; Davila O; Shah N; Gale RP; Kamble R; Diaz MA; Lazarus HM; Savani BN; Hildebrandt GC; Solh M; Freytes CO; Lee C; Kyle RA; Usmani SZ; Ganguly S; Assal A; Berdeja J; Kanate AS; Dhakal B; Meehan K; Kindwall-Keller T; Saad A; Locke F; Seo S; Nishihori T; Gergis U; Gasparetto C; Mark T; Nieto Y; Kumar S; Hari P
Biol Blood Marrow Transplant; 2019 Apr; 25(4):683-688. PubMed ID: 30579965
[TBL] [Abstract][Full Text] [Related]
53. Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.
Romano A; Parrinello NL; Consoli ML; Marchionni L; Forte S; Conticello C; Pompa A; Corso A; Milone G; Di Raimondo F; Borrello I
Ann Hematol; 2015 Nov; 94(11):1875-83. PubMed ID: 26223359
[TBL] [Abstract][Full Text] [Related]
54. Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome.
Trakada G; Kastritis E; Gavriatopoulou M; Velentza L; Fotiou D; Ziogas DC; Panagiotidis I; Eleutherakis-Papaiakovou E; Roussou M; Migkou M; Kanellias N; Ntanasis-Stathopoulos I; Kallianos A; Terpos E; Dimopoulos MA
Ann Hematol; 2019 Jun; 98(6):1427-1434. PubMed ID: 30834954
[TBL] [Abstract][Full Text] [Related]
55. [Predictive Value of Pre-treatment Serum Uric Acid Level for Prognosis in Newly Diagnosed Patients with Multiple Myeloma].
Xu SQ; Zhao P; Wang ZH; Deng H; Zhang L; Wei J; Zou XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1216-1223. PubMed ID: 34362505
[TBL] [Abstract][Full Text] [Related]
56. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Gagelmann N; Eikema DJ; Koster L; Caillot D; Pioltelli P; Lleonart JB; Reményi P; Blaise D; Schaap N; Trneny M; Passweg J; Porras RP; Cahn JY; Musso M; Poiré X; Fenk R; Itälä-Remes M; Pavone V; Fouillard L; Maertens J; Bron D; Pouli A; Schroyens W; Schönland S; Garderet L; Yakoub-Agha I; Kröger N
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2134-2142. PubMed ID: 31288095
[TBL] [Abstract][Full Text] [Related]
57. No outcome disparities in patients with diffuse large B-cell lymphoma and a low socioeconomic status.
Boslooper K; Hoogendoorn M; van Roon EN; Kibbelaar RE; Storm H; Hovenga S; Woolthuis G; van Rees BP; Klijs B; Veeger NJGM; Kluin-Nelemans HC; de Bock GH
Cancer Epidemiol; 2017 Jun; 48():110-116. PubMed ID: 28463808
[TBL] [Abstract][Full Text] [Related]
58. Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.
Terpos E; Anargyrou K; Katodritou E; Kastritis E; Papatheodorou A; Christoulas D; Pouli A; Michalis E; Delimpasi S; Gkotzamanidou M; Nikitas N; Koumoustiotis V; Margaritis D; Tsionos K; Stefanoudaki E; Meletis J; Zervas K; Dimopoulos MA;
Int J Cancer; 2012 Feb; 130(3):735-42. PubMed ID: 21484787
[TBL] [Abstract][Full Text] [Related]
59. [Clinical Characteristics and Survival Analysis of Patients with IgD Multiple Myeloma].
Gao XY; Ma YP; Chao Y; Fan L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):547-552. PubMed ID: 33812429
[TBL] [Abstract][Full Text] [Related]
60. Adverse prognostic impact of bone marrow microvessel density in multiple myeloma.
Lee N; Lee H; Moon SY; Sohn JY; Hwang SM; Yoon OJ; Youn HS; Eom HS; Kong SY
Ann Lab Med; 2015 Nov; 35(6):563-9. PubMed ID: 26354343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
